1. KD. Tripathi. Haematinics and Erythropoietin. Essentials of medical pharmacology. Seventh edition. 2013. Page – 605-606.
2. Kenneth Kaushansky and Thomas J. Kipps. Hematopoietic Agents: Growth factor, Minerals and Vitamins. Goodman & Gilman’s: The Pharmacological basics of Therapeutics. 12th Edition. New York McGraw Hill Medical 2011. Page – 1083-1085.
3. American Regent, Inc. Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Standard of Care in Treating Iron Deficiency Anemia. NIH U.S. National Library of Medicine ClinicalTrials.gov. [Revised on February 2018] [Accessed 21st December 2020] https://clinicaltrials.gov/ct2/show/NCT00703937
4. Amreen Naqash, Rifat Ara, Ghulam N Bader. Effectiveness and safety of ferric carboxymaltose compared to iron sucrose in women with iron deficiency anemia: phase IV clinical trials. NIH National Library of Medicine, National center for biotechnology information. Pubmed.gov. January 2018. [Accessed 21st December 2020] https://pubmed.ncbi.nlm.nih.gov/29304848/
5. Vifor France. Electronic Medicines Compendium (EMC); [Revised on October 2020] [Accessed 21st December 2020] https://www.medicines.org.uk/emc/files/pil.5910.pdf
6. Vifor (International) Inc, Switzerland. U.S. Food & Drug Administration. [Revised on January 2018] [Accessed 21st December 2020] https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/203565s005lbl.pdf